drugset / Trial / NCT00005092

Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

NCT00005092

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy used to kill tumor cells. Sometimes the transplanted cells are rejected by the body's normal tissues. Transplanting donated cells that have been treated with psoralen may prevent this from happening. PURPOSE: Phase I trial to study the effectiveness of chemotherapy, radiation therapy, and psoralen-treated donor cells in treating patients who are undergoing peripheral stem cell transplantation for hematologic cancer.

Timeline

Start
1999-05-28
Primary completion
2002-08-28
Completion
2002-08-28

Drugs

EvaluationDrugModalityDoseRoute
Background Cyclophosphamide Other / unclassified Intravenous
Background Psoralen Small molecule
Background Thiotepa Other / unclassified Intravenous